International Flavors & Fragrances
IFF
$75.08
-0.99%
International Flavors & Fragrances Inc. (IFF) is the world's largest producer of specialty ingredients, operating in the Chemicals - Specialty industry. The company develops and sells proprietary formulations for flavors, fragrances, health, food, and personal care products, serving as a critical partner to consumer goods companies globally. The current investor narrative is focused on the company's ongoing strategic transformation, including the planned divestiture of its Food Ingredients business, and its efforts to stabilize profitability and cash flow generation following a period of significant volatility, as evidenced by recent quarterly results showing a return to positive net income after a challenging start to the year.…
IFF
International Flavors & Fragrances
$75.08
Related headlines
Investment Opinion: Should I buy IFF Today?
Rating & Thesis: Hold. IFF is a compelling turnaround story with improving cash flow and a clear strategic path, but persistent revenue declines and elevated valuation on an EBITDA basis warrant caution until execution is proven. This view is anchored by the bullish analyst consensus but tempered by the company's fundamental challenges.
Supporting Evidence: The recommendation is supported by four key data points: 1) Positive and improving free cash flow generation ($256M TTM), 2) A reasonable forward P/E of 15.94x based on consensus EPS of $5.32, implying expected earnings recovery, 3) Strong technical momentum with 15.16% gains over three months, and 4) A manageable debt-to-equity ratio of 0.47. However, these are counterbalanced by a negative trailing net margin (-3.3%) and a high EV/EBITDA of 29.93x.
Risks & Conditions: The two biggest risks are a failure to arrest the revenue decline and a compression of the elevated EBITDA multiple. This Hold rating would upgrade to a Buy if quarterly revenue growth turns positive in the core segments or if the forward P/E compresses below 14x on sustained earnings momentum. It would downgrade to a Sell if quarterly revenue declines accelerate beyond -8% YoY or if the company reports a return to significant net losses. Relative to its own history and given the execution risk, the stock is currently fairly valued, not clearly overvalued or undervalued.
Sign up to view all
IFF 12-Month Price Forecast
IFF is at an inflection point. The technical momentum and analyst bullishness reflect genuine optimism about the strategic transformation and earnings recovery, as captured in the reasonable forward P/E. However, the persistent revenue decline and elevated trailing EV/EBITDA multiple are legitimate concerns that cap the upside and define the risk. The base case of a gradual, messy recovery is most probable. The stance would upgrade to Bullish on confirmation of revenue stabilization in the core business post-divestiture. It would turn Bearish if the next quarterly report shows the revenue decline worsening or if the divestiture is canceled.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $97.60 and implied upside of +30.0% versus the current price.
Average Target
$97.60
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$60 - $98
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, which is low for a company of IFF's market cap and can lead to higher volatility and less efficient price discovery. The consensus sentiment, based on recent institutional ratings, is bullish, with firms like Mizuho, Barclays, Wells Fargo, and Citigroup maintaining 'Outperform' or 'Buy' equivalents, and Oppenheimer upgrading to 'Outperform' in February 2026. The average revenue estimate for the next period is $11.96 billion, with a tight range between $11.79 billion (low) and $12.19 billion (high), indicating strong consensus on the top-line outlook. The average EPS estimate is $5.32, with a narrow range from $5.22 to $5.45, suggesting analysts have a high degree of conviction in the near-term profitability trajectory, though the limited number of contributors means this consensus may be less robust than for more widely covered stocks.
Bulls vs Bears: IFF Investment Factors
The evidence presents a balanced but cautiously optimistic picture. The bull case is currently stronger, primarily driven by powerful technical momentum, a clear strategic transformation plan, and improving quarterly cash flow and profitability. However, the bear case is substantiated by persistent revenue declines, weak overall profitability, and an elevated EV/EBITDA multiple. The single most important tension in the investment debate is the execution risk of the strategic transformation. If IFF successfully divests its Food Ingredients unit, stabilizes its core revenue, and expands margins as expected, the forward P/E of 15.9x will appear cheap. If execution falters or revenue declines accelerate, the high EV/EBITDA multiple and negative ROE will justify a significant re-rating lower.
Bullish
- Strong Technical Momentum & Recovery: The stock has gained 15.16% over the last three months and 16.65% over the last six months, significantly outperforming the S&P 500's 9.72% gain over six months. Trading at $76.72, it is near its 52-week high of $84.45, indicating a robust recovery trend and investor optimism.
- Analyst Consensus Bullish with Clear Targets: Institutional sentiment is bullish, with firms like Mizuho, Barclays, and Citigroup maintaining 'Outperform' or 'Buy' ratings. The average analyst EPS estimate of $5.32 for the forward period implies a forward P/E of 15.94x, suggesting confidence in a significant earnings recovery.
- Positive Free Cash Flow & Improving Profitability: The company generated $132 million in free cash flow in Q4 2025, contributing to a trailing twelve-month FCF of $256 million. Q4 2025 net income turned positive at $18 million, a significant recovery from the Q1 2025 net loss of -$1.018 billion, signaling a potential stabilization.
- Strategic Transformation & Divestiture Focus: The planned divestiture of the Food Ingredients business ($802M in a recent period) aims to streamline operations and focus on higher-margin core segments (Taste, Scent, Health & Biosciences). This strategic pivot is central to the investor narrative for future margin improvement and debt reduction.
Bearish
- Persistent Revenue Decline & Top-Line Pressure: Q4 2025 revenue of $2.589 billion represents a -6.6% year-over-year decline, continuing a trend of sequential quarterly decreases from $2.844 billion in Q1 2025. This indicates fundamental challenges in driving growth even before the planned divestiture.
- Weak Profitability Metrics & Negative ROE: The trailing twelve-month net margin is negative at -3.3%, and the operating margin is a thin 7.7%. Return on Equity (ROE) is negative at -2.55%, signaling inefficient use of shareholder capital despite recent quarterly improvements.
- Elevated Valuation on EBITDA Basis: The trailing EV/EBITDA multiple is elevated at 29.93x, which is high for a company with inconsistent earnings. This suggests the market is pricing in a significant future normalization of earnings, leaving little room for error in the execution of the strategic plan.
- Limited Analyst Coverage & High Short Interest: Only 5 analysts provide estimates, which can lead to less efficient price discovery and higher volatility. A short ratio of 5.85 indicates a significant portion of the market remains skeptical about the company's near-term prospects.
IFF Technical Analysis
The stock is in a clear recovery trend, having gained 15.16% over the last three months and 16.65% over the last six months, significantly outperforming the S&P 500's 15.14% and 9.72% gains over the same periods, respectively. With a current price of $76.72, the stock is trading at approximately 91% of its 52-week high of $84.45, indicating strong momentum and positioning near the upper bound of its annual range, which suggests investor optimism but also raises the risk of overextension. Recent momentum has been positive but volatile, with a 6.57% gain over the past month, which notably outperformed the S&P 500's 0.74% gain, as shown by a relative strength of +5.83; however, this short-term strength contrasts with a weak 1-year performance of only +2.44%, which severely underperformed the broader market's +24.99% return, highlighting a significant divergence and a potential catch-up rally in progress. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $84.45 and support at the 52-week low of $59.14; a decisive breakout above $84.45 would signal a resumption of the long-term uptrend, while a breakdown below the recent consolidation range could test lower support levels. The stock's beta of 0.956 indicates volatility roughly in line with the overall market, which is notable for a materials sector company and suggests its price movements are more driven by idiosyncratic fundamentals than broad market swings.
Beta
0.96
0.96x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$59-$84
Price range past year
Annual Return
+1.1%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | -2.2% |
| 3m | +5.7% | +15.8% |
| 6m | +11.3% | +6.4% |
| 1y | +1.1% | +20.9% |
| ytd | +10.4% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
Revenue growth remains challenged, with Q4 2025 revenue of $2.589 billion representing a -6.6% year-over-year decline, continuing a trend of sequential quarterly revenue decreases from $2.844 billion in Q1 2025. Segment data from a recent period shows the Taste ($588M), Scent ($610M), and Health & Biosciences ($589M) segments are of similar scale, while the Food Ingredients unit ($802M) is the largest but slated for divestiture, indicating the core future business is currently experiencing top-line pressure. Profitability is inconsistent but showed improvement in the latest quarter, with Q4 2025 net income turning positive at $18 million (net margin of 0.7%) and gross margin at 29.2%, a significant recovery from the massive Q1 2025 net loss of -$1.018 billion; however, the trailing twelve-month net margin remains negative at -3.3%, and the operating margin is a thin 7.7%, reflecting ongoing margin compression from prior-year levels. The balance sheet is moderately leveraged but cash-generative, with a debt-to-equity ratio of 0.47 and a current ratio of 1.42 indicating adequate short-term liquidity. The company generated $318 million in operating cash flow and $132 million in free cash flow in Q4 2025, contributing to a trailing twelve-month free cash flow of $256 million; the Return on Equity (ROE) is negative at -2.55%, signaling inefficient use of shareholder capital, but the positive free cash flow provides a foundation for debt reduction and funding the ongoing portfolio transformation.
Quarterly Revenue
$2.6B
2025-12
Revenue YoY Growth
-0.06%
YoY Comparison
Gross Margin
+0.29%
Latest Quarter
Free Cash Flow
$256000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Given the company's negative trailing net income and positive EBITDA, the EV/EBITDA multiple is the most appropriate primary valuation metric. The trailing EV/EBITDA is 29.93x, which is elevated and reflects the market's focus on normalized earnings power post-transformation, while the forward P/E of 15.94x, based on estimated EPS of $5.32, suggests the market expects a significant earnings recovery. Peer comparison is challenging due to a lack of provided industry average multiples, but the stock's Price/Sales (P/S) ratio of 1.58x and Price/Book (P/B) ratio of 1.22x can be contextualized against its own history to assess relative value. Historically, the stock's valuation has been highly volatile, with its P/E ratio swinging from deeply negative figures to over 239x in recent quarters; the current forward P/E of 15.9x sits well below historical peaks seen in 2021-2023, suggesting the market is not pricing in overly optimistic growth expectations despite the recent price recovery and may be accounting for the uncertainty surrounding the business transformation.
PE
-46.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -651x~339x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IFF faces significant financial risks stemming from inconsistent profitability and revenue pressure. The trailing twelve-month net margin of -3.3% and an operating margin of only 7.7% reflect ongoing margin compression. While Q4 showed a positive net income of $18 million, this follows a massive Q1 loss of -$1.018 billion, indicating high earnings volatility. The company's revenue has declined sequentially for three quarters, with Q4 revenue down 6.6% YoY, raising concerns about the underlying health of its core business segments even before the planned divestiture.
Market & Competitive Risks: The primary market risk is valuation compression, given the stock's elevated trailing EV/EBITDA of 29.93x. If the expected earnings recovery does not materialize swiftly, this multiple could contract sharply. The stock's beta of 0.956 indicates its volatility is in line with the market, but its 1-year underperformance of over 22% relative to the S&P 500 shows it has been subject to severe sector or company-specific headwinds. Competitive pressures in the specialty chemicals space and potential disruptions during the business divestiture process add further external threats.
Worst-Case Scenario: The worst-case scenario involves a failure to execute the Food Ingredients divestiture on favorable terms, coupled with a continued decline in core segment revenue and a reversion to sustained quarterly losses. This could trigger analyst downgrades, a loss of investor confidence, and a rush for the exits given the high short interest. The realistic downside could see the stock retesting its 52-week low of $59.14, representing a potential loss of approximately -23% from the current price of $76.72. A drawdown to this level would be consistent with the stock's maximum drawdown of -24.93% observed in the recent data.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Continued revenue decline and weak profitability, evidenced by a -3.3% net margin and -2.55% ROE. 2) Execution Risk: Failure to successfully complete the Food Ingredients divestiture or realize expected cost savings. 3) Valuation Risk: High trailing EV/EBITDA of 29.93x could compress if recovery is delayed. 4) Sentiment Risk: Low analyst coverage (only 5 analysts) and high short interest (5.85) can amplify volatility on news flow.
The 12-month forecast is bifurcated. The base case (50% probability) sees the stock trading between $75 and $84, as the company's transformation proceeds with mixed results. The bull case (30% probability) targets a range of $84 to $92 on successful divestiture and revenue stabilization. The bear case (20% probability) warns of a drop toward the 52-week low of $59 if execution falters. The most likely scenario is the base case, which assumes the company meets analyst EPS estimates of $5.32 but continues to struggle with top-line growth.
IFF's valuation sends mixed signals. On a trailing basis, it appears expensive with an EV/EBITDA of 29.93x and a negative trailing P/E. However, the forward P/E of 15.94x, based on consensus EPS of $5.32, is reasonable and suggests the market is paying a fair price for expected recovery, not a premium for high growth. Compared to its own history, the forward multiple is well below past peaks. Therefore, the stock is likely fairly valued relative to its near-term earnings potential, but carries risk if those earnings fail to materialize.
IFF is a speculative buy for investors comfortable with turnaround stories and execution risk. The bullish analyst consensus and 15.9x forward P/E suggest the market expects an earnings recovery, offering potential upside to the 52-week high of $84.45. However, it is not a 'good buy' for conservative investors, given the persistent -6.6% revenue decline, negative ROE, and high short interest of 5.85. It could be a good buy for a tactical portfolio allocation if an investor has high conviction in management's ability to execute the divestiture and stabilize the core business.
IFF is more suitable for a medium-term investment horizon of 12-24 months. It is not ideal for short-term trading due to its market-aligned beta of 0.956 and the binary nature of upcoming transformation catalysts, which could cause sharp moves. It is also not a classic long-term 'buy and hold' stock until the turnaround is proven and sustainable revenue growth is established. The lack of a meaningful dividend (0.02% yield) further reduces its appeal for income-focused long-term holders. A minimum holding period through the next few earnings reports and the divestiture announcement is advised.